Notice of Intent to Publish a Funding Opportunity Announcement for Integrated Approaches to HIV-Related Heart, Lung, Blood, and Sleep Comorbidities (R01)

Notice Number: NOT-HL-16-441

Key Dates
Release Date: September 13, 2016

Estimated Publication Date of Announcement: Winter 2016
First Estimated Application Due Date: Spring 2017
Earliest Estimated Award Date: February 2018
Earliest Estimated Start Date: February 2018

Related Announcements

Issued by
National Heart, Lung, and Blood Institute (NHLBI)


The National Heart, Lung, and Blood Institute intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for research on the molecular mechanisms underlying HIV-related heart, lung, blood, and sleep (HLBS) comorbidities.

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

The FOA is expected to be published in Winter 2016 with intended application due dates in Spring and Winter 2017.

This FOA will utilize the R01 activity code. Details of the planned FOA are provided below.

Research Initiative Details

Synergistic "system biology" approaches that combine experimental omics, computational methods, and clinical endpoints have the potential to open new avenues for research in HIV-related HLBS abnormalities, which are associated with a complex interplay of HIV, inflammation, antiretroviral therapy, co-infections, and traditional risk factors. The intended FOA solicits applications that propose systems biology approaches using clinical samples from HIV-infected patients to elucidate the biological perturbations and mechanisms underlying HIV-related HLBS comorbidities. Investigations must utilize clinical samples and other informative clinical data (e.g., imaging) from HIV-infected subjects that are already available or will be collected to characterize the pathogenesis of HIV-related HLBS comorbidities using multiple omics approaches to the extent possible. The ultimate goal is to better understand disease progression, which may help identify new therapeutic targets that pre-empt the onset of HLBS complications in the HIV population.

Applicants are encouraged, but not required to use a multiple program director/principal investigator (PD/PI) mechanism to facilitate collaborations between HIV and HLBS investigators.  Areas of expertise that may be represented include infectious diseases, immunology, cell biology, "omics" (including genomics, transcriptomics, proteomics, epigenomics, metabolomics, and the handling of large data sets), molecular biology, and computational modeling.



Please direct all inquiries to:

Renee Wong, Ph.D.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-451-6808